Table 1.
Characteristics of Study Populations
| MACS |
SHCS |
|||
| Variable | Cases (n = 30) | Controls (n = 81) | Cases (n = 53) | Controls (n = 149) |
| Gender, N (%) | ||||
| Male | 30 (100%) | 81 (100%) | 33 (77%) | 118 (79%) |
| Female | 0 (0%) | 0 (0%) | 10 (23%) | 31 (21%) |
| Age, median (IQR) | 39 (36, 44) | 40 (36,51) | 39 (34, 43) | 38 (35, 43) |
| Race/ethnicity, N (%) | ||||
| White | 29 (97%) | 79 (98%) | 44 (83%) | 129 (87%) |
| Black | 0 (0%) | 2 (2%) | 1 (2%) | 8 (5%) |
| Other/unknown | 1 (3%) | 0 (0%) | 8 (15%) | 12 (8%) |
| Ever IV drug use, N (%) | ||||
| No | 26 (87%) | 71 (88%) | 32 (60%) | 70 (47%) |
| Yes | 4 (13%) | 10 (12%) | 21 (40%) | 79 (53%) |
| Ever smoking, N (%) | ||||
| No | 7 (23%) | 31 (38%) | NA | NA |
| Yes | 23 (77%) | 50 (62%) | NA | NA |
| Years on study, median (IQR) | 6.6 (4.0, 8.4) | 7.1 (4.9, 9.3) | 4.6 (0.25, 7.8) | 6.4 (1.8, 9.7) |
| PML diagnostic criteria | ||||
| Histological/virological | 16 (53%) | NA | 25 (47%) | NA |
| Clinical/radiographic | 14 (47%) | NA | 28 (53%) | NA |
| Calendar Yr Dx, median (IQR) | 1991 (1989, 1994) | NA | 1999 (1997, 2002) | NA |
| Entry CD4, median (IQR) | 549 (363, 631) | 483 (375, 636) | 274 (90, 440) | 216 (105, 430) |
| CD4 at Dx, median (IQR) | 139 (87, 206) | 171 (90, 280) | 139 (44, 257) | 120 (57, 218) |
| cART in 2 yrs before PML | ||||
| No | 29 (97%) | 81 (100%) | 23 (43%) | NA |
| Yes | 1 (3%) | 0 (0%) | 30 (57%) | NA |
Abbreviations: cART, combined antiretroviral therapy; IQR, interquartile range; MACS, Multicenter AIDS Cohort Study; NA, not available; SHCS, Swiss HIV Cohort Study.